Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

This trial is testing a three-drug combination — quizartinib, decitabine, and venetoclax — for people with a type of blood cancer called acute myeloid leukemia (AML) or a high-risk form of a bone marrow disorder called myelodysplastic syndrome (MDS), either newly diagnosed or returned after prior treatment. **You may be eligible if...** - You have been diagnosed with AML (with 20% or more abnormal blood cells in the marrow) or high-risk MDS (more than 10% abnormal cells) - For newly diagnosed patients: you are not a candidate for standard chemotherapy, or you have AML with a specific genetic mutation (FLT3) - For relapsed/refractory patients: your cancer came back or did not respond to prior treatment - You are in adequate overall health with acceptable blood and organ function **You may NOT be eligible if...** - You have a subtype called acute promyelocytic leukemia (APL) - You have active heart rhythm problems (such as a prolonged QT interval) or are on medications that affect heart rhythm - You have active infection or severe organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.